Abstract
Invasive mould infections are a major cause of morbidity and mortality in hematopoietic stem cell transplant recipients (HSCT). Allogeneic HSCT recipients are at substantially higher risk than autologous HSCT recipients. Although neutropenia following the conditioning regimen remains an important risk factor for opportunistic fungal infections, most cases of invasive mould infection in allogeneic HSCT recipients occur after neutrophil recovery in the setting of potent immunosuppressive therapy for graft-versus-host disease. Invasive aspergillosis is the most common mould infection. However, there has been an increased incidence of less common non-Aspergillus moulds that include zygomycetes, Fusarium sp., and Scedosporium sp. Reflecting a key need, important advances have been made in the antifungal armamentarium. Voriconazole has become a new standard of care as primary therapy for invasive aspergillosis based on superiority over amphotericin B. There is significant interest in combination therapy for invasive aspergillosis pairing voriconazole or an amphotericin B formulation with an echinocandin. There have also been advances in novel diagnostic methods that facilitate early detection of invasive fungal infections that include galactomannan and beta-glucan antigen detection and PCR using fungal specific primers. We review the epidemiology, diagnosis, and management of invasive mould infection in HSCT, with a focus on allogeneic recipients. We also discuss options for prevention and early treatment of invasive mould infections.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
TJ Walsh A Groll J Hiemenz R Fleming E Roilides E Anaissie (2004) ArticleTitleInfections due to emerging and uncommon medically important fungal pathogens Clin Microbiol Infect 10 IssueIDSuppl 1 48–66 Occurrence Handle14748802 Occurrence Handle10.1111/j.1470-9465.2004.00839.x
BN Jahagirdar VA Morrison (2002) ArticleTitleEmerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients Semin Respir Infect 17 IssueID2 113–120 Occurrence Handle12070830 Occurrence Handle10.1053/srin.2002.33446
KA Marr RA Carter F Crippa A Wald L Corey (2002) ArticleTitleEpidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis 34 IssueID7 909–917 Occurrence Handle11880955 Occurrence Handle10.1086/339202
L Romani (2004) ArticleTitleImmunity to fungal infections Nat Rev Immunol 4 IssueID1 1–23 Occurrence Handle14661066 Occurrence Handle10.1038/nri1255 Occurrence Handle1:CAS:528:DC%2BD3sXpsV2rsrw%3D
DA Stevens (2004) ArticleTitleVaccinate against aspergillosis! A call to arms of the immune system Clin Infect Dis 38 IssueID8 1131–1136 Occurrence Handle15095219 Occurrence Handle10.1086/382882
BJ Kullberg AM Oude Lashof MG Netea (2004) ArticleTitleDesign of efficacy trials of cytokines in combination with antifungal drugs Clin Infect Dis 39 IssueIDSuppl 4 S218–S223 Occurrence Handle15546121 Occurrence Handle10.1086/421960
BH Segal J Kwon-Chung TJ Walsh BS Klein M Battiwalla NG Almyroudis SM Holland L Romani (2006) ArticleTitleImmunotherapy for fungal infections Clin Infect Dis 42 IssueID4 507–515 Occurrence Handle16421795 Occurrence Handle1:CAS:528:DC%2BD28XhvFymsr0%3D Occurrence Handle10.1086/499811
BH Segal TJ Walsh (2005) ArticleTitleCurrent approaches to diagnosis and treatment of invasive aspergillosis Am J Respir Crit Care Med 173 707–717 Occurrence Handle16387806 Occurrence Handle10.1164/rccm.200505-727SO Occurrence Handle1:CAS:528:DC%2BD28Xms1Cgsbw%3D
CL Mackall RE Gress (1997) ArticleTitlePathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy Immunol Rev 157 61–72 Occurrence Handle9255622 Occurrence Handle1:STN:280:DyaK2szpvFCqtw%3D%3D Occurrence Handle10.1111/j.1600-065X.1997.tb00974.x
J Morgan KA Wannemuehler KA Marr S Hadley DP Kontoyiannis TJ Walsh SK Fridkin PG Pappas DW Warnock (2005) ArticleTitleIncidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program Med Mycol 43 IssueIDSuppl 1 S49–S58 Occurrence Handle16110792 Occurrence Handle10.1080/13693780400020113
A Wald W Leisenring JA Burik Particlevan RA Bowden (1997) ArticleTitleEpidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation [see comments] J Infect Dis 175 IssueID6 1459–1466 Occurrence Handle9180187 Occurrence Handle1:STN:280:DyaK2szitl2qsw%3D%3D Occurrence Handle10.1086/516480
JW Baddley TP Stroud D Salzman PG Pappas (2001) ArticleTitleInvasive mold infections in allogeneic bone marrow transplant recipients Clin Infect Dis 32 IssueID9 1319–1324 Occurrence Handle11303267 Occurrence Handle1:STN:280:DC%2BD3MzpsFantQ%3D%3D Occurrence Handle10.1086/319985
WB Grow JS Moreb D Roque K Manion H Leather V Reddy SA Khan KJ Finiewicz H Nguyen CJ Clancy PS Mehta JR Wingard (2002) ArticleTitleLate onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital Bone Marrow Transplant 29 IssueID1 15–19 Occurrence Handle11840139 Occurrence Handle1:STN:280:DC%2BD387hvVGhtA%3D%3D Occurrence Handle10.1038/sj.bmt.1703332
E Jantunen P Ruutu L Niskanen L Volin T Parkkali P Koukila-Kahkola T Ruutu (1997) ArticleTitleIncidence and risk factors for invasive fungal infections in allogeneic BMT recipients Bone Marrow Transplant 19 IssueID8 801–808 Occurrence Handle9134172 Occurrence Handle1:STN:280:DyaK2s3nvFOqug%3D%3D Occurrence Handle10.1038/sj.bmt.1700737
PH McWhinney CC Kibbler MD Hamon OP Smith L Gandhi LA Berger RK Walesby AV Hoffbrand HG Prentice (1993) ArticleTitleProgress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years’ experience Clin Infect Dis 17 IssueID3 397–404 Occurrence Handle8218680 Occurrence Handle1:STN:280:DyaK2c%2Fjt1ymtA%3D%3D
KY Yuen PC Woo MS Ip RH Liang EK Chiu H Siau PL Ho FF Chen TK Chan (1997) ArticleTitleStage-specific manifestation of mold infections in bone marrow transplant recipients: Risk factors and clinical significance of positive concentrated smears Clin Infect Dis 25 IssueID1 37–42 Occurrence Handle9243031 Occurrence Handle1:STN:280:DyaK2szos12lug%3D%3D
KA Marr RA Carter M Boeckh P Martin L Corey (2002) ArticleTitleInvasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 100 IssueID13 4358–4366 Occurrence Handle12393425 Occurrence Handle1:CAS:528:DC%2BD38XpsFCqs7Y%3D Occurrence Handle10.1182/blood-2002-05-1496
A Shaukat F Bakri P Young T Hahn D Ball MR Baer M Wetzler JL Slack P Loud M Czuczman PL McCarthy TJ Walsh BH Segal (2005) ArticleTitleInvasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics Mycopathologia 159 IssueID2 181–188 Occurrence Handle15770441 Occurrence Handle10.1007/s11046-004-5495-0
T Fukuda M Boeckh RA Carter BM Sandmaier MB Maris DG Maloney PJ Martin RF Storb KA Marr (2003) ArticleTitleInvasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: Risks and outcomes Blood 10 10
Walsh TJ, Roden M, Nelson L, Knudsen T, Venzon D, Segal B, Barrett J, Childs R. Invasive Fungal Infections Complicating Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). ICAAC, 42nd meeting, San Diego, CA, 2002
EA Hagen H Stern D Porter K Duffy K Foley S Luger SJ Schuster EA Stadtmauer MG Schuster (2003) ArticleTitleHigh rate of invasive fungal infections following nonmyeloablative allogeneic transplantation Clin Infect Dis 36 IssueID1 9–15 Occurrence Handle12491195 Occurrence Handle10.1086/344906
AR Alam G Varma T Hahn B Segal P Paplham J Becker M Baer B Bambach J Silva J Slack M Wetzler PL McCarthy SuffixJr (2002) ArticleTitleInfectious complications in long-term survivors of cord blood stem cell transplantation (CBSCT): Experience at Roswell Park Cancer Institute Blood 100 629(s)
DW Denning P Ribaud N Milpied D Caillot R Herbrecht E Thiel A Haas M Ruhnke H Lode (2002) ArticleTitleEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 IssueID5 563–571 Occurrence Handle11807679 Occurrence Handle1:CAS:528:DC%2BD38XitlCitbg%3D Occurrence Handle10.1086/324620
TF Patterson WR Kirkpatrick M White JW Hiemenz JR Wingard B Dupont MG Rinaldi DA Stevens JR Graybill (2000) ArticleTitleInvasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore) 79 IssueID4 250–260 Occurrence Handle1:STN:280:DC%2BD3cvhsVGnsg%3D%3D Occurrence Handle10.1097/00005792-200007000-00006
R Herbrecht DW Denning TF Patterson JE Bennett RE Greene JW Oestmann WV Kern KA Marr P Ribaud O Lortholary R Sylvester RH Rubin JR Wingard P Stark C Durand D Caillot E Thiel PH Chandrasekar MR Hodges HT Schlamm PF Troke B Pauw Particlede (2002) ArticleTitleVoriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 IssueID6 408–415 Occurrence Handle12167683 Occurrence Handle1:CAS:528:DC%2BD38XlvFKrt7o%3D Occurrence Handle10.1056/NEJMoa020191
T Fukuda M Boeckh RA Carter BM Sandmaier MB Maris DG Maloney PJ Martin RF Storb KA Marr (2003) ArticleTitleRisks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood 102 IssueID3 827–833 Occurrence Handle12689933 Occurrence Handle1:CAS:528:DC%2BD3sXlvFCmsLs%3D Occurrence Handle10.1182/blood-2003-02-0456
FM Marty SJ Lee MM Fahey EP Alyea RJ Soiffer JH Antin LR Baden (2003) ArticleTitleInfliximab use in patients with severe graft-versus-host disease and other emerging risk factors for non-Candida invasive fungal infections in allogeneic hematopoietic transplant recipients: A cohort study Blood 102 2768–2776 Occurrence Handle12855583 Occurrence Handle1:CAS:528:DC%2BD3sXotF2ntbY%3D Occurrence Handle10.1182/blood-2003-01-0267
SG Filler MR Yeaman DC Sheppard (2005) ArticleTitleTumor necrosis factor inhibition and invasive fungal infections Clin Infect Dis 41 IssueIDSuppl 3 S208–S212 Occurrence Handle15983902 Occurrence Handle1:CAS:528:DC%2BD2MXotFWkt74%3D Occurrence Handle10.1086/430000
F Crippa L Holmberg RA Carter H Hooper KA Marr W Bensinger T Chauncey L Corey M Boeckh (2002) ArticleTitleInfectious complications after autologous CD34-selected peripheral blood stem cell transplantation Biol Blood Marrow Transplant 8 IssueID5 281–289 Occurrence Handle12064366 Occurrence Handle10.1053/bbmt.2002.v8.pm12064366
J Berenguer MC Allende JW Lee K Garrett C Lyman NM Ali J Bacher PA Pizzo TJ Walsh (1995) ArticleTitlePathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression Am J Respir Crit Care Med 152 IssueID3 1079–1086 Occurrence Handle7663787 Occurrence Handle1:STN:280:DyaK2Mzpt1ymsA%3D%3D
Chamilos G, Luna M, Lewis RE, Safdar A, Bodey GP, Raad II, Kontoyiannis DP. Invasive fungal infections (IFIs) in patients (pts) with hematological malignancies (1989–2003): An autopsy study. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005: M-720
S Schwartz M Ruhnke P Ribaud L Corey T Driscoll OA Cornely U Schuler I Lutsar P Troke E Thiel (2005) ArticleTitleImproved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 IssueID8 2641–2645 Occurrence Handle15998833 Occurrence Handle1:CAS:528:DC%2BD2MXhtFantbvF Occurrence Handle10.1182/blood-2005-02-0733
DW Denning (1996) ArticleTitleTherapeutic outcome in invasive aspergillosis Clin Infect Dis 23 IssueID3 608–615 Occurrence Handle8879787 Occurrence Handle1:STN:280:DyaK2s%2FjsVWgsw%3D%3D
TJ Walsh I Lutsar T Driscoll B Dupont M Roden P Ghahramani M Hodges AH Groll JR Perfect (2002) ArticleTitleVoriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children Pediatr Infect Dis J 21 240–248 Occurrence Handle12005089 Occurrence Handle10.1097/00006454-200203000-00015
WJ Steinbach DK Benjamin SuffixJr DP Kontoyiannis JR Perfect I Lutsar KA Marr MS Lionakis HA Torres H Jafri TJ Walsh (2004) ArticleTitleInfections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases Clin Infect Dis 39 IssueID2 192–198 Occurrence Handle15307028 Occurrence Handle10.1086/421950
J Maertens I Raad G Petrikkos M Boogaerts D Selleslag FB Petersen CA Sable NA Kartsonis A Ngai A Taylor TF Patterson DW Denning TJ Walsh (2004) ArticleTitleEfficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 IssueID11 1563–1571. Occurrence Handle15578352 Occurrence Handle1:CAS:528:DC%2BD2cXhtFGgtr3I Occurrence Handle10.1086/423381
CG Dennis WR Greco Y Brun R Youn HK Slocum RJ Bernacki R Lewis N Wiederhold SM Holland R Petraitiene TJ Walsh BH Segal (2006) ArticleTitleEffect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease Antimicrob Agents Chemother 50 IssueID2 422–427 Occurrence Handle16436692 Occurrence Handle1:CAS:528:DC%2BD28XhsFegtrs%3D Occurrence Handle10.1128/AAC.50.2.422-427.2006
WR Kirkpatrick S Perea BJ Coco TF Patterson (2002) ArticleTitleEfficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis Antimicrob Agents Chemother 46 IssueID8 2564–2568 Occurrence Handle12121933 Occurrence Handle1:CAS:528:DC%2BD38XlsFGit7Y%3D Occurrence Handle10.1128/AAC.46.8.2564-2568.2002
V Petraitis R Petraitiene AA Sarafandi AM Kelaher CA Lyman HE Casler T Sein AH Groll J Bacher NA Avila TJ Walsh (2003) ArticleTitleCombination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin J Infect Dis 187 IssueID12 1834–1843 Occurrence Handle12792859 Occurrence Handle1:CAS:528:DC%2BD3sXls1Gjt78%3D Occurrence Handle10.1086/375420
JC Luque KV Clemons DA Stevens (2003) ArticleTitleEfficacy of micafungin alone or in combination against systemic murine aspergillosis Antimicrob Agents Chemother 47 1452–1455 Occurrence Handle12654692 Occurrence Handle1:CAS:528:DC%2BD3sXivVSmsLY%3D Occurrence Handle10.1128/AAC.47.4.1452-1455.2003
PH Chandrasekar JL Cutright EK Manavathu (2004) ArticleTitleEfficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive aspergillosis Clin Microbiol Infect 10 925–928 Occurrence Handle15373889 Occurrence Handle1:STN:280:DC%2BD2cvmsVOiuw%3D%3D Occurrence Handle10.1111/j.1469-0691.2004.00958.x
O Sivak K Bartlett V Risovic E Choo F Marra DS Batty KM Wasan (2004) ArticleTitleAssessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis J Pharm Sci 93 1382–1389 Occurrence Handle15124198 Occurrence Handle1:CAS:528:DC%2BD2cXks12iurk%3D Occurrence Handle10.1002/jps.20080
JR Graybill R Bocanegra GM Gonzalez LK Najvar (2003) ArticleTitleCombination antifungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin J Antimicrob Chemother 52 656–662 Occurrence Handle12972452 Occurrence Handle1:CAS:528:DC%2BD3sXnvVCjsbw%3D Occurrence Handle10.1093/jac/dkg425
TB Aliff PG Maslak JG Jurcic ML Heaney KN Cathcart KA Sepkowitz MA Weiss (2003) ArticleTitleRefractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin Cancer 97 IssueID4 1025–1032 Occurrence Handle12569602 Occurrence Handle1:CAS:528:DC%2BD3sXhsFOnsbY%3D Occurrence Handle10.1002/cncr.11115
DP Kontoyiannis R Hachem RE Lewis GA Rivero HA Torres J Thornby R Champlin H Kantarjian GP Bodey II Raad (2003) ArticleTitleEfficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer 98 IssueID2 292–299 Occurrence Handle12872348 Occurrence Handle1:CAS:528:DC%2BD3sXlvFChsr8%3D Occurrence Handle10.1002/cncr.11479
KA Marr M Boeckh RA Carter HW Kim L Corey (2004) ArticleTitleCombination antifungal therapy for invasive aspergillosis Clin Infect Dis 39 IssueID6 797–802 Occurrence Handle15472810 Occurrence Handle1:CAS:528:DC%2BD2cXoslent7o%3D Occurrence Handle10.1086/423380
Maertens J, Glasmacher A, Herbrecht R, Aoun M, Thiebaut A, Cordonnier C, Segal B, Caillot D, Sable C, Killar J, Taylor A, Kartsonis, Patterson T. Multicenter, noncomparative study of caspofungin (CAS) combined with other antifungals in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to prior therapy (rx): Final data. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-954)
Raad I, S. Chapman, R. Bradsher, V. Morrison, M. Goldman, J. Graybill, J. R. Perfect, T. Patterson, T. Walsh, G. Corcoran, and P. Pappas. 2004. Posaconazole (POS) salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC (M-669)
F Offner C Cordonnier P Ljungman HG Prentice D Engelhard D Bacquer ParticleDe F Meunier B Pauw ParticleDe (1998) ArticleTitleImpact of previous aspergillosis on the outcome of bone marrow transplantation Clin Infect Dis 26 IssueID5 1098–1103 Occurrence Handle9597235 Occurrence Handle1:STN:280:DyaK1c3lvFGhsQ%3D%3D
T Fukuda M Boeckh KA Guthrie DK Mattson S Owens A Wald BM Sandmaier L Corey RF Storb KA Marr (2004) ArticleTitleInvasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center Biol Blood Marrow Transplant 10 IssueID7 494–503 Occurrence Handle15205670 Occurrence Handle10.1016/j.bbmt.2004.02.006
A Imhof SA Balajee DN Fredricks JA Englund KA Marr (2004) ArticleTitleBreakthrough fungal infections in stem cell transplant recipients receiving voriconazole Clin Infect Dis 39 IssueID5 743–746 Occurrence Handle15356792 Occurrence Handle10.1086/423274
Marty FM, Cosimi L, Marasco WA, Rubin RH, Baden LR. Breakthrough zygomycosis in allogeneic hematopoietic stem cell transplant recipients who received voriconazole as prophylaxis or empiric therapy. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. M-985, 2003
DP Kontoyiannis MS Lionakis RE Lewis G Chamilos M Healy C Perego A Safdar H Kantarjian R Champlin TJ Walsh II Raad (2005) ArticleTitleZygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: A case control observational study of 27 recent cases J Infect Dis 191 1350–1360 Occurrence Handle15776383 Occurrence Handle10.1086/428780
DP Kontoyiannis VC Wessel GP Bodey KV Rolston (2000) ArticleTitleZygomycosis in the 1990s in a tertiary-care cancer center Clin Infect Dis 30 IssueID6 851–856 Occurrence Handle10852735 Occurrence Handle1:STN:280:DC%2BD3cvisVOgtQ%3D%3D Occurrence Handle10.1086/313803
MM Roden TE Zaoutis WL Buchanan TA Knudsen TA Sarkisova RL Schaufele M Sein T Sein CC Chiou JH Chu DP Kontoyiannis TJ Walsh (2005) ArticleTitleEpidemiology and outcome of zygomycosis: a review of 929 reported cases Clin Infect Dis 41 IssueID5 634–653 Occurrence Handle16080086 Occurrence Handle10.1086/432579
RN Greenberg K Mullane JA Burik Particlevan I Raad MJ Abzug G Anstead R Herbrecht A Langston KA Marr G Schiller M Schuster JR Wingard CE Gonzalez SG Revankar G Corcoran RJ Kryscio R Hare (2006) ArticleTitlePosaconazole as salvage therapy for zygomycosis Antimicrob Agents Chemother 50 IssueID1 126–133 Occurrence Handle16377677 Occurrence Handle1:CAS:528:DC%2BD28XivVGltA%3D%3D Occurrence Handle10.1128/AAC.50.1.126-133.2006
D.P. Kontoyiannis, R. Hare, H. Solomon, M. Corrado, and J. A. van Burik. 2005. Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, M-974
EI Boutati EJ Anaissie (1997) ArticleTitleFusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management Blood 90 IssueID3 999–1008 Occurrence Handle9242529 Occurrence Handle1:CAS:528:DyaK2sXkvVWht74%3D
EJ Anaissie RT Kuchar JH Rex A Francesconi M Kasai FM Muller M Lozano-Chiu RC Summerbell MC Dignani SJ Chanock TJ Walsh (2001) ArticleTitleFusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections Clin Infect Dis 33 IssueID11 1871–1878 Occurrence Handle11692299 Occurrence Handle1:STN:280:DC%2BD3MnktVGlsg%3D%3D Occurrence Handle10.1086/324501
I Raad J Tarrand H Hanna M Albitar E Janssen M Boktour G Bodey M Mardani R Hachem D Kontoyiannis E Whimbey K Rolston (2002) ArticleTitleEpidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer Infect Control Hosp Epidemiol 23 IssueID9 532–537 Occurrence Handle12269452 Occurrence Handle10.1086/502102
M Nucci KA Marr F Queiroz-Telles CA Martins P Trabasso S Costa JC Voltarelli AL Colombo A Imhof R Pasquini A Maiolino CA Souza E Anaissie (2004) ArticleTitleFusarium infection in hematopoietic stem cell transplant recipients Clin Infect Dis 38 IssueID9 1237–1242 Occurrence Handle15127334 Occurrence Handle10.1086/383319
JR Perfect KA Marr TJ Walsh RN Greenberg B DuPont J la Torre-Cisneros Particlede G Just-Nubling HT Schlamm I Lutsar A Espinel-Ingroff E Johnson (2003) ArticleTitleVoriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 IssueID9 1122–1131 Occurrence Handle12715306 Occurrence Handle1:CAS:528:DC%2BD3sXksFSgtb4%3D Occurrence Handle10.1086/374557
HA Torres RY Hachem RF Chemaly DP Kontoyiannis Raad SuffixII (2005) ArticleTitlePosaconazole: a broad-spectrum triazole antifungal Lancet Infect Dis 5 IssueID12 775–785 Occurrence Handle16310149 Occurrence Handle1:CAS:528:DC%2BD2MXhtlelu7jE Occurrence Handle10.1016/S1473-3099(05)70297-8
JR Perfect (2005) ArticleTitleTreatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex Clin Infect Dis 40 IssueIDSuppl 6 S401–S408 Occurrence Handle15809926 Occurrence Handle1:CAS:528:DC%2BD2MXktleqt7s%3D Occurrence Handle10.1086/429331
DP Kontoyiannis GP Bodey H Hanna R Hachem M Boktour E Girgaway M Mardani Raad SuffixII (2004) ArticleTitleOutcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery Leuk Lymphoma 45 IssueID1 139–141 Occurrence Handle15061210 Occurrence Handle1:STN:280:DC%2BD2c7msleiug%3D%3D Occurrence Handle10.1080/1042819031000149386
F Silveira M Nucci (2001) ArticleTitleEmergence of black moulds in fungal disease: epidemiology and therapy Curr Opin Infect Dis 14 679–684 Occurrence Handle11964884 Occurrence Handle1:STN:280:DC%2BD383ivVWgsg%3D%3D
SJ Levine (1992) ArticleTitleAn approach to the diagnosis of pulmonary infections in immunosuppressed patients Semin Respir Infect 7 IssueID2 81–95 Occurrence Handle1439323 Occurrence Handle1:STN:280:DyaK3s%2FmslKksA%3D%3D
R Greene (2004) The Radiologic Spectrum of Pulmonary Aspergillosis. Advances Against Aspergillosis San Francisco San Francisco, CA
JE Kuhlman EK Fishman PA Burch JE Karp EA Zerhouni SS Siegelman (1987) ArticleTitleInvasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management Chest 92 95–99 Occurrence Handle3595255 Occurrence Handle1:STN:280:DyaL2s3ksFKmuw%3D%3D
D Caillot O Casasnovas A Bernard JF Couaillier C Durand B Cuisenier E Solary F Piard T Petrella A Bonnin G Couillault M Dumas H Guy (1997) ArticleTitleImproved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery J Clin Oncol 15 IssueID1 139–147 Occurrence Handle8996135 Occurrence Handle1:STN:280:DyaK2s7kvFehtQ%3D%3D
D Caillot JF Couaillier A Bernard O Casasnovas DW Denning L Mannone J Lopez G Couillault F Piard O Vagner H Guy (2001) ArticleTitleIncreasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia J Clin Oncol 19 IssueID1 253–259 Occurrence Handle11134220 Occurrence Handle1:STN:280:DC%2BD38%2Fls1Sqtw%3D%3D
J Maertens J Verhaegen K Lagrou J Eldere ParticleVan M Boogaerts (2001) ArticleTitleScreening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation Blood 97 IssueID6 1604–1610 Occurrence Handle11238098 Occurrence Handle1:CAS:528:DC%2BD3MXitFalt70%3D Occurrence Handle10.1182/blood.V97.6.1604
J Maertens J Eldere ParticleVan J Verhaegen E Verbeken J Verschakelen M Boogaerts (2002) ArticleTitleUse of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients J Infect Dis 186 IssueID9 1297–1306 Occurrence Handle12402199 Occurrence Handle1:CAS:528:DC%2BD38XovFKjtbw%3D Occurrence Handle10.1086/343804
R Herbrecht V Letscher-Bru C Oprea B Lioure J Waller F Campos O Villard KL Liu S Natarajan-Ame P Lutz P Dufour JP Bergerat E Candolfi (2002) ArticleTitleAspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients J Clin Oncol 20 IssueID7 1898–1906 Occurrence Handle11919250 Occurrence Handle10.1200/JCO.2002.07.004
LJ Wheat (2003) ArticleTitleRapid diagnosis of invasive aspergillosis by antigen detection Transpl Infect Dis 5 IssueID4 158–166 Occurrence Handle14987199 Occurrence Handle1:STN:280:DC%2BD2c7msVarsQ%3D%3D Occurrence Handle10.1111/j.1399-3062.2003.00031.x
MA Mennink-Kersten JP Donnelly PE Verweij (2004) ArticleTitleDetection of circulating galactomannan for the diagnosis and management of invasive aspergillosis Lancet Infect Dis 4 IssueID6 349–357 Occurrence Handle15172343 Occurrence Handle1:CAS:528:DC%2BD2cXltlCktLg%3D Occurrence Handle10.1016/S1473-3099(04)01045-X
KA Marr SA Balajee L McLaughlin M Tabouret C Bentsen TJ Walsh (2004) ArticleTitleDetection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance J Infect Dis 190 IssueID3 641–649. Occurrence Handle15243943 Occurrence Handle1:CAS:528:DC%2BD2cXmvF2ntL0%3D Occurrence Handle10.1086/422009
KA Marr M Laverdiere A Gugel W Leisenring (2005) ArticleTitleAntifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay Clin Infect Dis 40 1762–1769 Occurrence Handle15909264 Occurrence Handle1:CAS:528:DC%2BD2MXlsFyisLk%3D Occurrence Handle10.1086/429921
A Sulahian S Touratier P Ribaud (2003) ArticleTitleFalse positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam N Engl J Med 349 2366–2367 Occurrence Handle14668472 Occurrence Handle1:CAS:528:DC%2BD3sXpvVClu78%3D Occurrence Handle10.1056/NEJM200312113492424
TJ Walsh S Shoham R Petraitiene T Sein R Schaufele A Kelaher H Murray C Mya-San J Bacher V Petraitis (2004) ArticleTitleDetection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction J Clin Microbiol 42 IssueID10 4744–4748 Occurrence Handle15472335 Occurrence Handle1:CAS:528:DC%2BD2cXpvFKqu7k%3D Occurrence Handle10.1128/JCM.42.10.4744-4748.2004
Z Odabasi G Mattiuzzi E Estey H Kantarjian F Saeki RJ Ridge PA Ketchum MA Finkelman JH Rex L Ostrosky-Zeichner (2004) ArticleTitlebeta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis 39 IssueID2 199–205. Occurrence Handle15307029 Occurrence Handle1:CAS:528:DC%2BD2cXovVejtbs%3D Occurrence Handle10.1086/421944
Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654–659
Hachem RY, Boktour M, Daugherty T, Pham-Williams T, Warneke C, Chemaly RF, Raad II. The utillity of galactomannan enzyme immunoassay (GM-EIA) and (1,3) B-d-glucan (BD) in the diagnosis of invasive fungal infections in cancer patients. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-161)
JH Burik Particlevan W Leisenring D Myerson RC Hackman HM Shulman GE Sale RA Bowden GB McDonald (1998) ArticleTitleThe effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients Medicine (Baltimore) 77 IssueID4 246–254 Occurrence Handle10.1097/00005792-199807000-00003
JA Burik Particlevan V Ratanatharathorn DE Stepan CB Miller JH Lipton DH Vesole N Bunin DA Wall JW Hiemenz Y Satoi JM Lee TJ Walsh (2004) ArticleTitleMicafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 IssueID10 1407–1416 Occurrence Handle15546073 Occurrence Handle10.1086/422312
KA Marr F Crippa W Leisenring M Hoyle M Boeckh SA Balajee WG Nichols B Musher L Corey (2003) ArticleTitleItraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients Blood 2 2
DJ Winston RT Maziarz PH Chandrasekar HM Lazarus M Goldman JL Blumer GJ Leitz MC Territo (2003) ArticleTitleIntravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial Ann Intern Med 138 IssueID9 705–713 Occurrence Handle12729424 Occurrence Handle1:CAS:528:DC%2BD3sXktVyhsLg%3D
KA Marr W Leisenring F Crippa JT Slattery L Corey M Boeckh GB McDonald (2003) ArticleTitleCyclophosphamide metabolism is impacted by azole antifungals Blood 22 22
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo S, Greinix H, Azevedo W, Reddy V, Hardalo C, Patino H, Durrant S. Posaconazole (POS) vs. fluconazole (FLU) for prophylaxis for invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD): Results of a multicenter trial. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-716)
J Maertens K Theunissen G Verhoef J Verschakelen K Lagrou E Verbeken A Wilmer J Verhaegen M Boogaerts J Eldere ParticleVan (2005) ArticleTitleGalactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study Clin Infect Dis 41 IssueID9 1242–1250 Occurrence Handle16206097 Occurrence Handle1:CAS:528:DC%2BD2MXht1WisbfE Occurrence Handle10.1086/496927
JH Rex PG Pappas AW Karchmer J Sobel JE Edwards S Hadley C Brass JA Vazquez SW Chapman HW Horowitz M Zervos D McKinsey J Lee T Babinchak RW Bradsher JD Cleary DM Cohen L Danziger M Goldman J Goodman E Hilton NE Hyslop DH Kett J Lutz RH Rubin WM Scheld M Schuster B Simmons DK Stein RG Washburn L Mautner TC Chu H Panzer RB Rosenstein J Booth (2003) ArticleTitleA randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 IssueID10 1221–1228 Occurrence Handle12746765 Occurrence Handle1:CAS:528:DC%2BD3sXltVKjsbw%3D Occurrence Handle10.1086/374850
BJ Kullberg JD Sobel M Ruhnke PG Pappas C Viscoli JH Rex JD Cleary E Rubinstein LW Church JM Brown HT Schlamm IT Oborska F Hilton MR Hodges (2005) ArticleTitleVoriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 IssueID9495 1435–1442 Occurrence Handle16243088 Occurrence Handle1:CAS:528:DC%2BD2MXhtFeiu73J Occurrence Handle10.1016/S0140-6736(05)67490-9
DA Stevens JY Lee (1997) ArticleTitleAnalysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria Arch Int Med 157 IssueID16 1857–1862 Occurrence Handle1:CAS:528:DyaK2sXmtlGqtr4%3D Occurrence Handle10.1001/archinte.157.16.1857
Cornely OA, Maertens J, Winston DJ, Perfect J, Helfgott D, Ullmann AJ, Angulo D. Posaconazole (POS) vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): Impact on mortality. Abstract 722-b. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005
TJ Walsh RW Finberg C Arndt J Hiemenz C Schwartz D Bodensteiner P Pappas N Seibel RN Greenberg S Dummer M Schuster JS Holcenberg (1999) ArticleTitleLiposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 IssueID10 764–771 Occurrence Handle10072411 Occurrence Handle1:CAS:528:DyaK1MXhvFOqu7k%3D Occurrence Handle10.1056/NEJM199903113401004
JR Wingard MH White E Anaissie J Raffalli J Goodman A Arrieta (2000) ArticleTitleA randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group Clin Infect Dis 31 IssueID5 1155–1163 Occurrence Handle11073745 Occurrence Handle1:CAS:528:DC%2BD3MXhsVKhtg%3D%3D Occurrence Handle10.1086/317451
PH Chandrasekar JI Ito (2005) ArticleTitleAmphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients Clin Infect Dis 40 IssueIDSuppl 6 S392–S400 Occurrence Handle15809925 Occurrence Handle1:CAS:528:DC%2BD2MXktleqt7o%3D Occurrence Handle10.1086/429333
R Bowden P Chandrasekar MH White X Li L Pietrelli M Gurwith JA Burik Particlevan M Laverdiere S Safrin JR Wingard (2002) ArticleTitleA double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients Clin Infect Dis 35 IssueID4 359–366. Occurrence Handle12145716 Occurrence Handle1:CAS:528:DC%2BD38XmvFSgu70%3D Occurrence Handle10.1086/341401
J Mora-Duarte R Betts C Rotstein AL Colombo L Thompson-Moya J Smietana R Lupinacci C Sable N Kartsonis J Perfect (2002) ArticleTitleComparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 IssueID25 2020–2029 Occurrence Handle12490683 Occurrence Handle1:CAS:528:DC%2BD38Xps1Ojtbs%3D Occurrence Handle10.1056/NEJMoa021585
TJ Walsh H Teppler GR Donowitz JA Maertens LR Baden A Dmoszynska OA Cornely MR Bourque RJ Lupinacci CA Sable BE dePauw (2004) ArticleTitleCaspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 IssueID14 1391–1402 Occurrence Handle15459300 Occurrence Handle1:CAS:528:DC%2BD2cXotVOrsro%3D Occurrence Handle10.1056/NEJMoa040446
Ruhnke M, Kuse E, Chetchotisakd P, Arns Da Cunha C, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (Abstract M-722c)
Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, and Walsh T. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C/IC). 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-718)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhatti, Z., Shaukat, A., Almyroudis, N.G. et al. Review of Epidemiology, Diagnosis, and Treatment of Invasive Mould Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Mycopathologia 162, 1–15 (2006). https://doi.org/10.1007/s11046-006-0025-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11046-006-0025-x